BMS Collaborated with Volastra to Develop and Commercialize Novel Therapies for Cancer
Shots:
- Volastra to receive $30M up front & will be eligible to receive ~$1.1B in development, regulatory & commercial milestone along with royalties on global sales of any product commercialized by BMS that emerges from the collaboration
- Volastra will be responsible to conduct multiple activities for undisclosed targets & will also conduct all research activities through the development product for select targets. Under an exclusive license, BMS will lead the development, regulatory & commercialization activities of the development product
- The collaboration will utilize Volastra’s CINtech platform to identify CIN-related synthetic lethal targets & advance the novel therapies for cancer
Ref: Businesswire | Image: BMS
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
